All posts by: Michael Zand

About Michael Zand

Age-related macular degeneration may be treatable using viral injection gene therapy – Genetic Literacy Project

Continue reading

2017-05-30 NEWS

Genetic Literacy Project

Age-related macular degeneration may be treatable using viral injection gene therapy
Genetic Literacy Project
[R]esearchers from Johns Hopkins Medicine were looking for ways to treat a particular type of age-related macular degeneration (AMD) known as a wet AMD. It’s a rare and more severe form of the disease [that] causes new blood vessels to grow under the …

Continue reading

2017-05-30 NEWS

CBS News

FDA approves expanded uses for immunotherapy
CBS News
May 30, 2017, 8:12 AM | The FDA expanded the approved uses for an immunotherapy drug that has successfully treated certain lung cancers and melanoma. The treatment that triggers the body’s own defense system to fight cancer was used by former …
Keytruda drug treats cancer based on tumor’s genetics rather than its locationGenetic Literacy Project

all 3 news articles »

Continue reading

2017-05-30 NEWS

Devon Live

Baby Max can only survive with a constant supply of stem cells
Devon Live
A Devon family are swimming to Great Ormond Street Hospital to help a mum whose 15-month-old son has been diagnosed with very rare syndrome called Diskeratosis Congenita. Little Max Hilton’s treatment is reliant on a steady supply of stem cell donors …

Continue reading

2017-05-30 NEWS

Abeona Therapeutics Receives Rare Pediatric Disease Designation …
GlobeNewswire (press release)
Abeona’s Third Gene Therapy Program to Receive Rare Pediatric Disease Designation, expected to enable Priority Review Voucher.

and more »

Continue reading

2017-05-30 NEWS

Molecule Can Mask Cancer’s Pain, Helping the Disease Develop, Study Shows
Immuno-Oncology News
The PD-L1 molecule can mask cancer’s pain, enabling malignancies to develop and spread without sending alarms to the immune system, according to a study. Researchers from Duke University School of Medicine discovered that Opdivo (nivolumab) fights …